Method for producing pulverized organic compound particle
Disclosed is a method for producing pulverized particles of a crystalline organic compound which is poorly water-soluble. Also disclosed is a pulverized organic compound particle produced by such a method. Specifically disclosed is a method for producing a poor water solubility organic compound particle for medical use, which is characterized in that a poor water solubility organic compound for medical use is mixed with a physiologically acceptable salt and a physiologically acceptable polyol, and subjected to wet milling. Also specifically disclosed is a poor water solubility organic compound particle for medical use, which is produced by such a production method.
1. A method for producing poor water solubility organic compound fine particles for medical use comprising:
mixing a poor water solubility organic compound with at least one physiologically acceptable salt in the amount of 1- to 100-fold with respect to a mass of the poor water solubility organic compound and a physiologically acceptable polyol;
wet-milling the poor water solubility organic compound by the physiologically acceptable salt; and
removing the at least one physiologically acceptable salt and the physiologically acceptable polyol after the wet-milling,
wherein the poor water solubility organic compound has a melting point or a decomposition point in the range of 80 to 350 degrees C., and
the wet-milled poor water solubility organic compound fine particles maintain its crystal form as the poor water solubility organic compound has before the wet-milling process.
2. A method for producing poor water solubility organic compound fine particles for medical use according to claim 1 , wherein the physiologically acceptable polyol includes a viscosity modifier.
3. A method for producing poor water solubility organic compound fine particles for medical use according to claim 2 , wherein the viscosity of the polyol is 1000 mPa·s or more at 20 degrees C.
4. A method for producing poor water solubility organic compound fine particles for medical use according to claim 2 , wherein the viscosity modifier is citric acid, DL-malic acid, D-sorbitol, D-mannitol, maltitol, maltose, tartaric acid, glucose, erythritol, xylitol, D-xylose, trehalose, fructose, lactic acid, lactose, glycine, urea, maleic acid or malonic acid.
5. A method for producing poor water solubility organic compound fine particles for medical use according to claim 1 , wherein the polyol is glycerin, propylene glycol or polyethylene glycol.
6. A method for producing poor water solubility organic compound fine particles for medical use according to claim 1 , wherein the at least one physiologically acceptable salt is one or more materials selected from the group consisting of sodium chloride, potassium chloride, ammonium chloride, sodium sulfate, magnesium sulfate, potassium sulfate, calcium sulfate, sodium malate, sodium citrate, disodium citrate, sodium dihydrogen citrate, potassium dihydrogen citrate, sodium dihydrogen phosphate, potassium dihydrogen phosphate, disodium hydrogen phosphate and dipotassium hydrogen phosphate.
7. A method for producing poor water solubility organic compound fine particles for medical use according to claim 1 , comprising adding no surface active agent.
8. A method for producing poor water solubility organic compound fine particles for medical use according to claim 1 , wherein the poor water solubility organic compound is one or more organic compounds selected from the group consisting of nifedipine, nicardipine, nimodipine, dipyridamole, disopyramide, prazosin hydrochloride, prednisolone, cortisone acetate, dexamethasone, betamethasone, beclometasone dipropionate, fluticasone propionate, budesonide, fluocinolone acetonide, indomethacin, naproxen, ketoprofen, 7-[(3,5-dimethoxy-4-hydroxycinnamoyl)amino]-3-octyloxy-4-hydroxy-1-methyl-2 (1H) -quinolinone, phenytoin, phenacemide, ethotoin, primidone, diazepam, nitrazepam, clonazepam, digitoxin, spironolactone, triamterene, chlorthalidone, polythiazide, benzthiazide, griseofulvin, nalidixic acid, chloramphenicol, chlorzoxazone, phenprobamate, mequitazine, bisbentiamin, mitomycin C, bicalutamide, paclitaxel, ubenimex, dacarbazine, fluconazole, miconazole, rifampicin, triamcinolone acetonide, clemastine fumarate, pranlukast hydrate, zafirlukast, fenofibrate, dihydroxybenzophenone, dihydrocholesterol, beta-carotene, propyl gallate, cinnamic acid, saccharin, folic acid and maltol.
9. A method for producing poor water solubility organic compound fine particles for medical use according to claim 1 , wherein the average diameter of the poor water solubility organic compound fine particles is 600 nm or less.
10. A method for producing poor water solubility organic compound fine particles for medical use according to claim 1 , wherein a ratio of the poor water solubility organic compound fine particles with a diameter of 0.2 micron or less is 70% or more.
11. A method for producing poor water solubility organic compound fine particles for medical use according to claim 1 , wherein 90% median diameter of the poor water solubility organic compound fine particles is 600 nm or less.
12. A method for producing poor water solubility organic compound fine particles for medical use according to claim 1 , wherein the at least one physiologically acceptable salt is removed after the wet-milling.
13. A method for producing poor water solubility organic compound fine particles for medical use according to claim 1 , wherein the solubility of the poor water solubility organic compound for medical use in the physiologically acceptable polyol is 10% (mass/volume) or less, and the solubility of the at least one physiologically acceptable salt in the physiologically acceptable polyol is 10% (mass/volume) or less.
14. A method for producing poor water solubility organic compound fine particles for medical use according to claim 1 , wherein the at least one physiologically acceptable salt has an average particle size of 5 to 300 μm.